• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

NPJ Vaccines . Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity

tetano

Editor, Senior Moderator
NPJ Vaccines


. 2022 Apr 11;7(1):42.
doi: 10.1038/s41541-022-00463-3.
Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity


Hilary E Hendin[SUP] 1 2 [/SUP], Pierre-Olivier Lavoie[SUP] 3 [/SUP], Jason M Gravett[SUP] 1 2 [/SUP], Stéphane Pillet[SUP] 2 3 [/SUP], Pooja Saxena[SUP] 3 [/SUP], Nathalie Landry[SUP] 3 [/SUP], Marc-André D'Aoust[SUP] 4 [/SUP], Brian J Ward[SUP] 5 6 [/SUP]



Affiliations

Abstract

The binding of influenza hemagglutinin (HA) to sialic acid (SA) receptors plays a well-defined role in shaping infection but the impact of such binding on vaccine responses has not yet been explored. We generated a virus-like particle (VLP) vaccine bearing the HA of H1N1 A/California/07/09 that is unable to bind to its α(2,6)-linked SA receptor (H1[SUB]Y98F[/SUB]-VLP) and compared its immunogenicity and efficacy to a wild-type H1-VLP (H1[SUB]WT[/SUB]-VLP) in mice. The H1[SUB]Y98F[/SUB]-VLP elicited significantly stronger and more durable antibody responses (hemagglutination inhibition and microneutralization titers) and greater avidity maturation, likely attributable to improved germinal center formation. H1[SUB]Y98F[/SUB]-VLP also resulted in a robust population of IL-2[SUP]+[/SUP]TNFα[SUP]+[/SUP]IFNγ[SUP]-[/SUP] CD4[SUP]+[/SUP] T cells that correlated with antibody responses. Compared to H1[SUB]WT[/SUB]-VLP vaccination, mice immunized with H1[SUB]Y98F[/SUB]-VLP had 2.3-log lower lung viral loads and significantly lower pulmonary inflammatory cytokine levels 5 days post-challenge. These findings suggest that abrogation of HA-SA interactions may be a promising strategy to improve the quality and durability of influenza vaccine-induced humoral responses.
 
Back
Top Bottom